Petree Brandon, Gannon Whitney D, Petrovic Mark, Stokes John W, Adjei Enock, Smith Ryan J, Demarest Caitlin T, Hoetzenecker Konrad, Bacchetta Matthew, Trindade Anil J
Division of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN.
Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.
JHLT Open. 2025 Apr 24;9:100273. doi: 10.1016/j.jhlto.2025.100273. eCollection 2025 Aug.
The lung composite allocation score (CAS) aims to improve waitlist outcomes for lung transplant candidates by prioritizing characteristics that reflect transplant urgency, including extracorporeal membrane oxygenation bridge to lung transplant (ECMO-BTT). Whether ECMO-BTT has been impacted by CAS is unknown. We analyzed the Organ Procurement and Transplant Network database to examine differences in ECMO-BTT utilization and characteristics and outcomes between transplant recipients who were transplanted one year before and one year after CAS implementation. Lung transplant recipients who received ECMO-BTT in the post-CAS era were younger ( < 0.01), more likely to be on ECMO at transplant listing rather than be initiated after ( < 0.05), and had shorter waitlist time ( < 0.01). Waitlist time was shorter in the post-CAS era among recipients (even non-ECMO) with high allocation scores only. This may have contributed to decreased use of ECMO-BTT in the post-CAS era ( = 0.03). One-year post-transplant survival did not differ between eras for ECMO-BTT patients, though was significantly better in the CAS era for non-ECMO-BTT patients (92% vs 90%, < 0.01). We report initial results of ECMO-BTT utilization in the post-CAS era.
肺综合分配评分(CAS)旨在通过优先考虑反映移植紧迫性的特征来改善肺移植候选者的等待名单结果,这些特征包括体外膜肺氧合桥接肺移植(ECMO-BTT)。ECMO-BTT是否受到CAS的影响尚不清楚。我们分析了器官获取与移植网络数据库,以研究在CAS实施前一年和实施后一年接受移植的受者之间,ECMO-BTT的使用情况、特征及结果的差异。在CAS时代后接受ECMO-BTT的肺移植受者更年轻(<0.01),在移植登记时更有可能已经在接受ECMO治疗而非之后才开始(<0.05),并且等待名单时间更短(<0.01)。仅在分配分数高的受者(甚至非ECMO受者)中,CAS时代后的等待名单时间更短。这可能导致了CAS时代后ECMO-BTT使用的减少(=0.03)。对于接受ECMO-BTT的患者,不同时代的移植后一年生存率没有差异,不过对于非ECMO-BTT患者,CAS时代的生存率显著更高(92%对90%,<0.01)。我们报告了CAS时代后ECMO-BTT使用的初步结果。